Edition:
United States

MediciNova Inc (MNOV.OQ)

MNOV.OQ on NASDAQ Stock Exchange Global Market

6.51USD
3:59pm EST
Change (% chg)

$-0.30 (-4.41%)
Prev Close
$6.81
Open
$6.79
Day's High
$6.79
Day's Low
$6.38
Volume
53,368
Avg. Vol
33,602
52-wk High
$7.85
52-wk Low
$4.40

Latest Key Developments (Source: Significant Developments)

Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS
Thursday, 7 Dec 2017 06:00pm EST 

Dec 7 (Reuters) - Medicinova Inc ::MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS.MEDICINOVA INC - TRIAL ACHIEVED PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY, AND ALSO DEMONSTRATED EFFICACY TRENDS IN FAVOR OF MN-166.MEDICINOVA INC - THERE WERE 7 SERIOUS ADVERSE EVENTS (SAES) REPORTED DURING STUDY BUT NONE OF SAES WERE RELATED TO STUDY DRUG.MEDICINOVA INC - MN-166 DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE. ALL SUBJECTS IN STUDY RECEIVED 100 MG OF RILUZOLE PER DAY.MEDICINOVA INC - ALL TREATMENT-RELATED ADVERSE EVENTS (TRAES) WERE MILD TO MODERATE IN INTENSITY & NO SEVERE OR LIFE-THREATENING TRAES WERE REPORTED.  Full Article

Medicinova announces positive top-line results from the Sprint-MS Phase 2B trial of MN-166 (ibudilast)
Thursday, 26 Oct 2017 06:00am EDT 

Oct 26 (Reuters) - Medicinova Inc ::Medicinova announces positive top-line results from the Sprint-MS phase 2B trial of MN-166 (ibudilast) in progressive MS: achieved both primary endpoints including a significant reduction in whole brain atrophy and safety and tolerability.Medicinova Inc - ‍MN-166 demonstrated a statistically significant reduction in rate of progression of whole brain atrophy compared to placebo in study​.Medicinova Inc - ‍MN-166 was safe and well tolerated in study​.  Full Article

MediciNova sees loss per share for year ending Dec 31 of $0.31
Wednesday, 27 Jul 2016 07:44am EDT 

MediciNova Inc : Says expected loss per share for year ending December 31, 2016 is $0.31 .FY 2016 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.  Full Article

MediciNova receives notice of allowance for new patent covering MN-001 and MN-002 for the treatment of fibrosis
Tuesday, 26 Jul 2016 01:47am EDT 

MediciNova Inc :Says it received a notice of allowance from the U.S. Patent And Trademark Office (Uspto) for a pending patent application which covers Mn-001 (Tipelukast) and Mn-002 (A Major Metabolite Of Mn-001) for the treatment of “Fibrosis” which includes a broad range of fibrosis / fibrotic disease in different organs due to different causes.  Full Article

Medicinova receives notice of allowance for new patent covering MN-001 and MN-002 for treatment of Fibrosis
Sunday, 24 Jul 2016 08:02pm EDT 

Medicinova : Receives notice of allowance for new patent covering MN-001 and MN-002 for treatment of Fibrosis .Says once issued, patent maturing from this allowed patent application is expected to expire no earlier than June 2035.  Full Article

MediciNova completes off-floor distribution
Monday, 16 May 2016 09:20pm EDT 

MediciNova Inc : Says it completes the off-floor distribution of shares on May 17 .Says 800,000 shares of its common stock were sold at the price of 644 yen per share.  Full Article

MediciNova to offer off-floor distribution of 800,000 shares
Monday, 16 May 2016 03:20am EDT 

MediciNova Inc <4875.T>: Says it to offer an off-floor distribution of 800,000 shares of its stock at the price of 644 yen per share, on the Tokyo Stock Exchange on May 17 .Says the limitation for purchase of the distribution is up to 10,000 shares for each customer.  Full Article

MediciNova to offer off-floor distribution of shares
Tuesday, 10 May 2016 02:43am EDT 

MediciNova Inc : Says it to offer an off-floor distribution of 800,000 shares on Tokyo Stock Exchange between May 17 and May 19 . Says offering price will be determined based on the closing share price of the day before the distribution .Says the limitation for distribution is up to 1,000 shares for each customer.  Full Article

MediciNova Inc announces interim data from clinical trial of MN-166 (ibudilast) in ALS
Wednesday, 20 Apr 2016 06:00am EDT 

MediciNova Inc:Announces interim data from clinical trial of MN-166 in ALS presented at the American Academy of Neurology 68th annual meeting in Vancouver, Canada.No cluster of adverse events was differentially present in MN-166 treatment and placebo treatment subjects.  Full Article

MediciNova Inc announces Ryan Selhorn as new CFO
Thursday, 31 Mar 2016 06:30am EDT 

MediciNova Inc:Appoints Ryan Selhorn as new CFO effective March 31.  Full Article

BRIEF-Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS

* MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS